Dive Brief:
- Qiagen said it has launched the first FDA-approved companion diagnostic for identifying breast cancer patients who may benefit from treatment with Novartis’ Piqray (alpelisib).
- Novartis last week announced FDA approval of the kinase inhibitor designed specifically for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer patients with a PIK3CA mutation.
- Qiagen said it has a worldwide co-exclusive license from Johns Hopkins University for PCR-based companion diagnostics based on mutations in the PIK3CA gene.
Click here to read more via Med Tech Drive.